RESP302, SALBUTAMOL , RESP303 clinical trials

Phase 1/2a Trial to Evaluate the Safety, Tolerability and Efficacy of Nebulised RESP30X Nitric Oxide Formulations in Non-Cystic Fibrosis Bronchiectasis (NCFB) Patients with Pseudomonas Aeruginosa (Pa) or other Potentially Pathogenic Micro-organisms (PPMs).

This study is testing a new inhaled medicine, RESP30X, for people with a lung condition called non-cystic fibrosis bronchiectasis. We want to see if it's safe, how well people tolerate it, and if it helps fight common lung infections like *Pseudomonas aeruginosa*.